Mochida Pharmaceutical Co.,Ltd. (4534.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

14.3x

EV/EBITDA

7.0x

Market Cap

JPY 116.45B

MomentumView details →

1D Return

+0.15%

YTD Return

−7.92%

RSI (14)

51.2

ValuationView details →

P/E (Fwd)

14.3x

EV/EBITDA

7.0x

Market Cap

JPY 116.45B

RSI (14)

51.2

MomentumView details →

1D Return

+0.15%

YTD Return

−7.92%

ProfitabilityView details →

Gross Margin

48.06%

Net Margin

5.74%

EBITDA Margin

9.89%

ROE (TTM)

4.67%

ROA (TTM)

3.52%

Asset Turnover

0.64x

GrowthView details →

Revenue YoY

+6.18%

EPS YoY

+12.53%

FCF YoY

—

Revenue CAGR 3Y

−1.54%

EPS CAGR 3Y

−16.70%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

4.01x

Quick Ratio

3.33x

Div Yield

2.44%

Div Rate

—

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

108.88B

Net Income (TTM)

5.50B

Op. CF (TTM)

—

Next earningsOct 30, 2026 →

Latest newsMore news →

Mochida Pharmaceutical succeeded the manufacturing and marketing approval for the gout and hyperuricemia treatment 'Topirolic' from Fuji Pharmaceutical and acquired related assets including intellectual property rights.16d ago

Similar companies

Nxera Pharma Co.,Ltd.4565.T Oncolys BioPharma Inc.4588.T PeptiDream Inc.4587.T GNI Group Ltd.2160.T KAKEN PHARMACEUTICAL CO.,LTD.4521.T ZERIA PHARMACEUTICAL CO.,LTD.4559.T Find similar companies →

Latest newsMore news →

Mochida Pharmaceutical succeeded the manufacturing and marketing approval for the gout and hyperuricemia treatment 'Topirolic' from Fuji Pharmaceutical and acquired related assets including intellectual property rights.16d ago